In the fast growing African pharmaceutical market, UCL is banking upon a new product pipeline and aggressive marketing approach for brand promotion for some of its key products. A lot of emphasis is being put on the quality and affordability of the drugs therefore the management is putting their entire might in finding innovative ways to achieve this mission.
Among the generics, UCL has many products in its range covering various therapeutic segments.
The future business growth strategy includes a large share from the export market with an estimated growth target of 30 % by targeting carefully selected countries across the African continent.
Having achieved the WHO pre-qualification for 1 major product; LAMOZID, a fixed dose combination ARV, pursuit of pre – qualification for other products especially anti malarial range will enable the Company to double up their turnovers and profits for the next 5 years.
In addition to UCLs own range of products, the company is developing another line of business by importing the finished products for the niche market segments like Oncology products, Anesthesia and the latest drug delivery systems for diabetic patients. These new ventures shall boost up the profits for the company.